+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID06468098

Phase Ib Study of IBI363 Combined with Chemotherapy for Advanced Cancers to Assess Safety, Tolerability, and Early Effectiveness

Led by Innovent Biologics (Suzhou) Co. Ltd. · Updated on 2024-07-18

556

Participants Needed

1

Research Sites

78 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and preliminary effectiveness of a drug called IBI363 combined with chemotherapy or standard care in patients with advanced cancers. This Phase Ib, open-label multicenter study includes patients whose cancers have progressed after standard treatments or who are receiving first-line treatment in some cohorts. The study aims to assess how well IBI363 works and how safe it is in these advanced malignancies. Participants will receive IBI363 combined with chemotherapy or Investigators Choice Standard of Care, depending on their specific cancer type and treatment history. The study includes several groups focusing on different advanced cancers such as non-small cell lung cancer, colorectal cancer, biliary tract tumors, esophageal squamous cell carcinoma, gastric cancer, triple-negative breast cancer, and platinum-resistant ovarian cancer. Some groups involve patients who have failed prior therapies, while others include those receiving first-line treatment. Treatment is given according to each groups protocol and monitored carefully. During the study, participants will have regular assessments for adverse events up to 90 days after treatment and ongoing evaluations of cancer response and survival for up to two years. Researchers will monitor blood levels of IBI363 and immune responses as well. The study includes safety checks, physical exams, and imaging to measure tumors. Participants are expected to comply with visit schedules and follow-up assessments to help researchers understand the treatments impact and safety profile over time.

CONDITIONS

Brief Title

A Study of IBI363 in Subjects With Advanced Malignancies

Research Team

B

binbin Min

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here